CoChat
Sign Up
Cited by 63Gut microbiota and healthHepatitis C virus researchLiver Disease and Transplantation

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients

Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M. +4 more·2016·Alimentary Pharmacology & Therapeutics
DOI 10.1111/apt.13732
Open this paper in CoChat — free account

Abstract

Summary: Background: Eradication of hepatitis C virus (HCV) is increasing but its residual impact on the pro‐inflammatory milieu in cirrhosis, which is associated with gut dysbiosis, is unclear. Aim: To define the impact of sustained virological response (SVR) on gut dysbiosis and systemic inflammation in HCV cirrhosis patients. Methods: Cirrhotic out‐patients with HCV with/without SVR (achieved >1 year prior) and age‐matched healthy controls underwent serum and stool collection. Serum was analysed for IL‐6, TNF‐α and endotoxin while stool microbiota analysis was performed using multitagged pyrosequencing. Microbial comparisons were made using UNIFRAC and cirrhosis dysbiosis ratio (lower score indicates dysbiosis). Comparisons were performed between cirrhotics with/without SVR and controls vs. cirrhotic patients. Results: A total of 105 HCV cirrhotics and 45 age‐matched healthy controls were enrolled. Twenty‐one patients had achieved SVR using pegylated interferon + ribavrin a median of 15 months prior. No significant differences on demographics, cirrhosis severity, concomitant medications or diabetes were seen between cirrhotics with/without SVR. There was no significant difference in overall microbiota composition (UNIFRAC P = 0.3) overall or within specific microbial families (cirrhosis dysbiosis ratio median 1.3 vs. 1.0, P = 0.45) between groups with/without SVR. This also extended towards IL‐6, TNF‐α and endotoxin levels. Both cirrhosis groups, however, had significant dysbiosis compared to healthy controls [UNIFRAC P = 0.01, cirrhosis dysbiosis ratio (1.1 vs. 2.9, P < 0.001)] along with higher levels of endotoxin, IL‐6 and TNF‐α. Conclusions: Gut dysbiosis and a pro‐inflammatory systemic milieu, are found in HCV cirrhosis regardless of SVR. This persistent dysbiosis could contribute towards varying rates of improvement after HCV eradication in cirrhosis.

Integrity signals

Registry

Crossref · 10.1111/apt.13732

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current data suggest that dysbiosis and gut-liver axis alterations in patients with end-stage viral hepatitis and cirrhosis resemble those in cirrhosis from other causes.

    “Current data suggest that dysbiosis and alterations of the gut–liver axis in patients with end-stage viral hepatitis and cirrhosis are similar to alterations in patients with cirrhosis from other causes67.”

    From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [67]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Bajaj, J. S., Sterling, R. K., Betrapally, N. S., Nixon, D. E., Fuchs, M., Daita, K., Heuman, D. M., Sikaroodi, M., Hylemon, P. B., White, M. B., Ganapathy, D., & Gillevet, P. M.
Affiliations
  • Virginia Commonwealth University (US)
  • George Mason University (US)
Corresponding author
Bajaj, J. S.
ORCID
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2016-07-15
Volume
44
Issue
6
Pages
638-643
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
DOI
10.1111/apt.13732
OpenAlex
W2464296204
Cited by
63
References
30
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 5
FWCI
3.12
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Department of Veterans Affairs (CX10076)
  • NIAAA (RO1AA020203)
  • McGuire Research Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
hepatitis C virus, hepatitis C cirrhosis, sustained virological response, gut dysbiosis, systemic inflammation, gut microbiota, endotoxin, interleukin-6, TNF-α, pegylated interferon, ribavirin
MeSH terms
Adult, Aged, Antiviral Agents, Female, Hepatitis C, Humans, Inflammation, Interferons, Liver Cirrhosis, Male, Middle Aged, Outpatients, Ribavirin, Case-Control Studies, Hepacivirus, Microbiota, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review